Lu Chirag, Naushad Altaf A, R Manjunath P, Kalra Pramila, Selvan Chitra, Y P Ganavi, Kolla Bharathi, Sourabh Sagar, Gn Devamsh, S Nikitha
Endocrinology, Ramaiah Medical College, Bangalore, IND.
Gastroenterology, St. Johns Medical College, Bangalore, IND.
Cureus. 2023 Jul 10;15(7):e41671. doi: 10.7759/cureus.41671. eCollection 2023 Jul.
Pheochromocytoma is a catecholamine-secreting tumor arising from adrenomedullary chromaffin cells that has a varied clinical presentation. Identification of this tumor, which has episodic symptoms, is a diagnostic challenge for clinicians. Diagnosis at an appropriate time is important because it is associated with significant morbidity and mortality. This study aims to mitigate the limited availability of data in our geographical area.
To assess the clinical, biochemical, and radiological features and outcomes of patients diagnosed with pheochromocytoma at our center.
This is a retrospective study. Patients diagnosed with pheochromocytoma during 2015-2023 were included in the study. Clinical, biochemical, and radiological data were collected at presentation, post-surgery, discharge, and until the last follow-up; data were retrieved from hospital records. Statistical analysis was done using IBM Corp. Released 2011. IBM SPSS Statistics for Windows, Version 20.0. Armonk, NY: IBM Corp.
This study included 19 patients, of whom 10 (52.6%) were female. The most common clinical presentation was a hypertensive crisis in patients with pre-existing hypertension (63.1%), followed by headache (47.3%). The classical triad of headache, palpitation, and sweating was seen in only three patients (15.7%). The mean tumor size was 5.01±2.06 cm, with a range of 2.5 to 12 cm. All patients underwent adrenalectomy; six patients (31.5%) had perioperative complications, with post-operative hypotension being the most common at 21% (n = 4), followed by an acute coronary event during alpha blockade in one patient (0.05%) and an intra-operative hypertensive crisis in one patient (5%). A biochemical remission rate post-surgery was achieved in 17 (89.47%) patients.
Hypertensive crisis in patients with pre-existing hypertension was the predominant presenting feature in most of our patients. Female predominance was noted (52.3%) compared to males. Perioperative complications were observed in 31.5% of patients, with post-operative hypotension being the most common complication.
嗜铬细胞瘤是一种起源于肾上腺髓质嗜铬细胞的分泌儿茶酚胺的肿瘤，临床表现多样。识别这种具有发作性症状的肿瘤对临床医生来说是一项诊断挑战。在适当的时候进行诊断很重要，因为它与显著的发病率和死亡率相关。本研究旨在缓解我们所在地理区域数据有限的情况。
评估在我们中心被诊断为嗜铬细胞瘤的患者的临床、生化和放射学特征及预后。
这是一项回顾性研究。研究纳入了2015年至2023年期间被诊断为嗜铬细胞瘤的患者。在就诊时、术后、出院时以及直至最后一次随访时收集临床、生化和放射学数据；数据从医院记录中获取。使用IBM公司2011年发布的IBM SPSS Statistics for Windows 20.0版进行统计分析。纽约州阿蒙克市：IBM公司。
本研究包括19名患者，其中10名（52.6%）为女性。最常见的临床表现是已有高血压患者出现高血压危象（63.1%），其次是头痛（47.3%）。仅3名患者（15.7%）出现头痛、心悸和出汗的经典三联征。肿瘤平均大小为5.01±2.06厘米，范围为2.5至12厘米。所有患者均接受了肾上腺切除术；6名患者（31.5%）有围手术期并发症，术后低血压最为常见，占21%（n = 4），其次是1名患者（0.05%）在α受体阻滞剂治疗期间发生急性冠状动脉事件，1名患者（5%）在手术中出现高血压危象。17名（89.47%）患者术后实现了生化缓解。
在我们的大多数患者中，已有高血压患者出现高血压危象是主要的临床表现。与男性相比，女性占优势（52.3%）。31.5%的患者观察到围手术期并发症，术后低血压是最常见的并发症。
